Heighten Science Publications Inc.

Recombinant HCG vs Triptorelin Acetate Which Trigger Offers Superior Oocyte Maturity in IVF Cycles

—

by

Vishnu
in

Introduction:

Oocyte maturation plays a crucial role in the success of in vitro fertilization (IVF) treatments. This study compares the effectiveness of two commonly used ovulation triggersrecombinant Human Chorionic Gonadotropin (HCG) and Triptorelin acetateon oocyte maturity rates in women undergoing ICSI cycles.
Visit https://www.obstetricgynecoljournal.com/ for more groundbreaking research in reproductive and obstetric medicine.

Comparative Evaluation of Ovulation Triggers

This prospective randomized trial included 100 subfertile women aged 21–35 years undergoing ICSI. Participants were divided equally into two groups receiving either recombinant HCG or Triptorelin acetate as ovulation triggers. The aim was to determine which method yielded a higher percentage of mature (Metaphase II) oocytes.

Key Findings

  • Metaphase II (M2) Oocytes: Triptorelin acetate yielded significantly more M2 oocytes than recombinant HCG.
  • Follicle Count: Triptorelin acetate was associated with a higher number of follicles ≥10 mm.
  • Hormonal Profile: Patients triggered with Triptorelin acetate had higher AMH and serum estradiol levels.
  • Safety: Both triggers demonstrated comparable safety profiles and timing for oocyte retrieval.

A detailed analysis can be found in our main journal article.

Broader Clinical Implications

The American Society for Reproductive Medicine (ASRM) emphasizes the importance of individualized trigger protocols in controlled ovarian stimulation to enhance oocyte yield and minimize ovarian hyperstimulation risks. GnRH agonists like Triptorelin may simulate the natural LH and FSH surge more closely, potentially improving oocyte quality and IVF outcomes.

Further Reading and Resources

Conclusion

While both recombinant HCG and Triptorelin acetate are effective in inducing final oocyte maturation, Triptorelin acetate may offer superior outcomes in terms of the number and quality of mature oocytes. This study supports the use of GnRH agonist triggers, particularly for patients undergoing antagonist ICSI cycles.

For a comprehensive breakdown, read the full study at https://doi.org/10.29328/journal.cjog.1001064

Call-to-Action

Explore more studies at https://www.obstetricgynecoljournal.com/ and join the conversation by sharing your thoughts in the comments below!

Disclaimer: This content is generated using AI assistance and should be reviewed for accuracy and compliance before considering this article and its contents as a reference. Any mishaps or grievances raised due to the reusing of this material will not be handled by the author of this article.

Comments

Leave a comment